Literature DB >> 28364251

Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.

A F Marmolejo-Valencia1, K Martínez-Mayorga2.   

Abstract

Modulation of opioid receptors is the primary choice for pain management and structural information studies have gained new horizons with the recently available X-ray crystal structures. Herkinorin is one of the most remarkable salvinorin A derivative with high affinity for the mu opioid receptor, moderate selectivity and lack of nitrogen atoms on its structure. Surprisingly, binding models for herkinorin are lacking. In this work, we explore binding models of herkinorin using automated docking, molecular dynamics simulations, free energy calculations and available experimental information. Our herkinorin D-ICM-1 binding model predicted a binding free energy of -11.52 ± 1.14 kcal mol-1 by alchemical free energy estimations, which is close to the experimental values -10.91 ± 0.2 and -10.80 ± 0.05 kcal mol-1 and is in agreement with experimental structural information. Specifically, D-ICM-1 molecular dynamics simulations showed a water-mediated interaction between D-ICM-1 and the amino acid H2976.52, this interaction coincides with the co-crystallized ligands. Another relevant interaction, with N1272.63, allowed to rationalize herkinorin's selectivity to mu over delta opioid receptors. Our suggested binding model for herkinorin is in agreement with this and additional experimental data. The most remarkable observation derived from our D-ICM-1 model is that herkinorin reaches an allosteric sodium ion binding site near N1503.35. Key interactions in that region appear relevant for the lack of β-arrestin recruitment by herkinorin. This interaction is key for downstream signaling pathways involved in the development of side effects, such as tolerance. Future SAR studies and medicinal chemistry efforts will benefit from the structural information presented in this work.

Entities:  

Keywords:  Allosteric binding; Biased agonist; Functional selectivity; Herkinorin; Mu opioid receptor

Mesh:

Substances:

Year:  2017        PMID: 28364251     DOI: 10.1007/s10822-017-0016-7

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  82 in total

1.  Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.

Authors:  M Filizola; H O Villar; G H Loew
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

2.  Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.

Authors:  Karina Martinez-Mayorga; Kendall G Byler; Austin B Yongye; Marc A Giulianotti; Colette T Dooley; Richard A Houghten
Journal:  Eur J Med Chem       Date:  2013-05-30       Impact factor: 6.514

3.  Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor.

Authors:  K A Neve; M G Cumbay; K R Thompson; R Yang; D C Buck; V J Watts; C J DuRand; M M Teeter
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

4.  Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Authors:  C E Spivak; C L Beglan; B K Seidleck; L D Hirshbein; C J Blaschak; G R Uhl; C K Surratt
Journal:  Mol Pharmacol       Date:  1997-12       Impact factor: 4.436

5.  A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.

Authors:  M Minami; T Nakagawa; T Seki; T Onogi; Y Aoki; Y Katao; S Katsumata; M Satoh
Journal:  Mol Pharmacol       Date:  1996-11       Impact factor: 4.436

Review 6.  Recent advances in the pharmacological management of pain.

Authors:  Josée Guindon; Jean-Sébastien Walczak; Pierre Beaulieu
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

Authors:  Carol B Fowler; Irina D Pogozheva; Harry LeVine; Henry I Mosberg
Journal:  Biochemistry       Date:  2004-07-13       Impact factor: 3.162

8.  Validation of molecular docking programs for virtual screening against dihydropteroate synthase.

Authors:  Kirk E Hevener; Wei Zhao; David M Ball; Kerim Babaoglu; Jianjun Qi; Stephen W White; Richard E Lee
Journal:  J Chem Inf Model       Date:  2009-02       Impact factor: 4.956

9.  Propagation of conformational changes during μ-opioid receptor activation.

Authors:  Rémy Sounier; Camille Mas; Jan Steyaert; Toon Laeremans; Aashish Manglik; Weijiao Huang; Brian K Kobilka; Héléne Déméné; Sébastien Granier
Journal:  Nature       Date:  2015-08-05       Impact factor: 49.962

10.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

View more
  3 in total

1.  Encoding mu-opioid receptor biased agonism with interaction fingerprints.

Authors:  R Bruno Hernández-Alvarado; Abraham Madariaga-Mazón; Fernando Cosme-Vela; Andrés F Marmolejo-Valencia; Adel Nefzi; Karina Martinez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2021-10-29       Impact factor: 3.686

Review 2.  Side Effects of Opioids Are Ameliorated by Regulating TRPV1 Receptors.

Authors:  Xiaqing Wang; Chongyu Bao; Zhenjiang Li; Lupeng Yue; Li Hu
Journal:  Int J Environ Res Public Health       Date:  2022-02-18       Impact factor: 3.390

Review 3.  Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs.

Authors:  Samo Lešnik; Éva Bertalan; Urban Bren; Ana-Nicoleta Bondar
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.